Drug intelligence / Profile preview

dextromethorphan + guaifenesin + phenylephrine

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

dextromethorphan + guaifenesin + phenylephrine is a fixed-dose combination of three active ingredients used for the relief of symptoms associated with cold and respiratory infections. Dextromethorphan is an antitussive that suppresses the cough reflex by acting on the brain to decrease activity in the cough center[1][2]. Guaifenesin is an expectorant that helps loosen and thin mucus in the airways, making it easier to clear phlegm[3]. Phenylephrine is a decongestant that acts as a selective alpha-1 adrenergic receptor agonist, narrowing blood vessels in the nasal passages to reduce congestion[3]. This combination is indicated for temporary relief of cough due to minor throat and bronchial irritation, nasal congestion, and to help with mucus clearance[3].

Brand names
Mucinex Fast-Max Severe Congestion and CoughChildren's Mucinex Multi-Symptom ColdChildren's Robitussin Cough and Cold CFRobitussin Cough and Cold CFSudafed PE Cold/Cough
02

Targets

SIGMAR1 (Sigma non-opioid intracellular receptor 1)ADRA1A (α1A)SERT (Sodium-dependent serotonin transporter)SMPD1 (Acid sphingomyelinase)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on dextromethorphan + guaifenesin + phenylephrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dextromethorphan + guaifenesin + phenylephrine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call